Concomitant chemoirradiation with vinorelbine and gefitinib induces additive effect in head and neck squamous cell carcinoma cell lines in vitro

Radiotherapy and Oncology

Volumn 85, Issue 1, 2007, Pages 138-145

  Erjala, Kaisa ^a   Zhang, Na ^a,b,c   Sundvall, Maria ^d,e   Kulmala, Jarmo ^a   Elenius, Klaus ^a,d,e   Grénman, Reidar ^a,d,e  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b CHINA MEDICAL UNIVERSITY   (China)

^c From Thoracic Surgery   (China)

^d UNIVERSITY OF TURKU   (Finland)

^e UNIVERSITY OF TURKU   (Finland)

Author keywords

Chemoirradiation; Concomitant; Gefitinib; HNSCC; Vinorelbine

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; NAVELBINE; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR 3; QUINAZOLINE DERIVATIVE; VINBLASTINE;

AREA UNDER THE CURVE; ARTICLE; CANCER CELL CULTURE; CELL CULTURE; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; DRUG EFFECT; GROWTH INHIBITION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; INCUBATION TIME; LARYNX; LINEAR ACCELERATOR; MOUTH TUMOR; PHOTON; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; WESTERN BLOTTING; DRUG ANTAGONISM; DRUG POTENTIATION; HEAD AND NECK TUMOR; MULTIMODALITY CANCER THERAPY; PATHOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DRUG SYNERGISM; HEAD AND NECK NEOPLASMS; HUMANS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3; VINBLASTINE;

EID: 35248875257     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2007.09.011     Document Type: Article

References (57)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Zbaeren P., and Lehmann W. Frequency and sites of distant metastases in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 113 (1987) 762-764
3. Garavello W., Ciardo A., Spreafico R., et al. Risk factors for distant metastases in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 132 (2006) 762-766
4. Barkley Jr. H.T. Management of cervical lymph node metastases in squamous cell carcinoma of the tonsillar fossa, base of tongue, supraglottic larynx, and hypopharynx. Am J Surg 124 (1972) 426-427
5. Pignon J.P., Bourhis J., Domenge C., et al. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 355 9208 (2000) 949-955
6. Bernier J., Domenge C., Ozsahin M., et al. European organization for research and treatment of cancer trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350 (2004) 1945-1952
7. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Radiation therapy oncology group 9501/intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous cell carcinoma of the head and neck. N Engl J Med 350 (2004) 1937-1944
8. Pignon J.P., Baujat B., and Bourhis J. Individual patient data meta-analyses in head and neck carcinoma: what have we learnt?. Cancer Radiother 9 (2005) 31-36
9. Cohen E.E., Rosen F., Stadler W.M., et al. Phase II Trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21 (2003) 1980-1987
10. Baselga J., Trigo J.M., Bourhis J., et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 23 (2005) 5568-5577
11. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
12. Grandis J.R., Melhem M.F., Barnes E.L., et al. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 78 (1996) 1284-1292
13. Grandis J.R., Melhem M.F., Gooding W.E., et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90 (1998) 824-832
14. O-charoenrat P., Modjtahedi H., Rhys-Evans P., et al. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. Cancer Res 60 (2000) 1121-1128
15. Ang K.K., Berkley B.A., Tu X., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62 (2002) 7350-7356
16. Ciardiello F., Caputo R., Bianco R., et al. Antitumor effect and potentiation of cytotoxic drug's activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6 (2000) 2053-2063
17. Wakeling A.E., Guy S.P., Woodburn J.R., et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 62 (2002) 5749-5754
18. Erjala K., Sundvall M., Junttila T.T., et al. Signaling via ErbB2 and ErbB3 associates with resistance and EGFR amplification with sensitivity to EGFR-inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 12 (2006) 4103-4111
19. Al-Hazzaa A., Bowen I.D., Randerson P., et al. The effect of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor, in combination with cisplatin, on apoptosis in SCC-15 cells. Cell Prolif 38 (2005) 77-86
20. Ranson M., Hammond L.A., Ferry D., et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 20 (2002) 2240-2250
21. LoRusso P.M., Herbst R.S., Rischin D., et al. Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors. Clin Cancer Res 9 (2003) 2040-2048
22. Johnson S.A., Harper P., Hortobagyi G.N., et al. Vinorelbine: an overview. Cancer Treat Rev 22 (1996) 127-142
23. Cros S., Wright M., Morimoto M., et al. Experimental anti-tumour activity of Navelbine. Semin Oncol 16 (1989) 15-20
24. Testolin A., Recher G., Gristoferi V., et al. Vinorelbine (NVB) in pretreated advanced head and neck squamous-cell carcinoma: a phase II study. Invest New Drugs 12 (1994) 231-234
25. Degardin M., Oliveira J., Geoffrois L., et al. An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Ann Oncol 9 (1998) 1103-1107
26. Erjala K., Pulkkinen J., Kulmala J., et al. Head and neck squamous cell carcinoma is highly sensitive to vinorelbine in vitro. Anticancer Res 22 (2002) 3135-3142
27. Erjala K., Pulkkinen J., Kulmala J., et al. Concomitant vinorelbine and radiation in head and neck squamous cell carcinoma in vitro. Acta Oncol 43 (2004) 169-174
28. Shintani S., Li C., Mihara M., et al. Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer. Int J Cancer 107 (2003) 1030-1037
29. Mavroudis D., Efstathiou E., Polyzos A., et al. A phase I-II trial of gefitinib in combination with vinorelbine and oxaliplatin as salvage therapy in women with advanced ovarian cancer (AOC). Am Soc Clin Oncol Meet Proc 23 (2004) 18 abstr 5020
30. Kim E.S., Khuri F.R., and Herbst R.S. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 13 (2001) 506-513
31. Lansford C.D., Grénman R., Bier H., et al. Chapter 28: head and neck cancers. In: Masters J.R.W., and Palsson B. (Eds). Human cell culture Vol. II (1999), Kluwer Academic Publishers, Great Britain 185-255
32. Grénman R., Burk D., Virolainen E., et al. Clonogenic cell assay for anchorage-dependent squamous cell carcinoma cell lines using limiting dilution. Int J Cancer 44 (1989) 131-136
33. Kulmala J., Rantanen V., Pekkola-Heino K., et al. Dosimetry of irradiation models: the 96-well clonogenic assay for testing radiosensitivity of cell lines. Acta Oncol 34 (1995) 105-109
34. Kainulainen V., Sundvall M., Määttä J.A., et al. A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival of chemotaxis. J Biol Chem 275 (2000) 8641-8649
35. Raitanen M., Rantanen V., Kulmala J., et al. Paclitaxel combined with fractionated radiation in vitro: a study with vulvar squamous cell carcinoma cell lines. Int J Cancer 97 (2002) 853-857
36. Machtay M., Rosenthal D.I., Hershock D., et al. Organ preservation therapy using induction plus concurrent chemoradiation for advanced resectable oropharyngeal carcinoma: a University of Pennsylvania Phase II Trial. J Clin Oncol 20 (2002) 3964-3971
37. Vokes E.E., Stenson K., Rosen F.R., et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 21 (2003) 320-326
38. Psyrri A., Kwong M., DiStasio S., et al. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up. J Clin Oncol 22 (2004) 3061-3069
39. Robert F., Ezekiel M.P., Spencer S.A., et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 19 (2001) 3234-3243
40. Huang S.M., Bock J.M., and Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59 (1999) 1935-1940
41. Saleh M.N., Raisch K.P., Stackhouse M.A., et al. Combined modality therapy of A431 human epidermoid cancer using anti-EGFR antibody C225 and radiation. Cancer Biother Radiopharm 14 (1999) 451-463
42. Bonner J.A., Raisch K.P., Trummel H.Q., et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 18 (2000) 47S-53S
43. Williams K.J., Telfer B.A., Stratford I.J., et al. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 86 (2002) 1157-1161
44. Bonner J.A., Maihle N.J., Folven B.R., et al. The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities. Int J Radiat Oncol Biol Phys 29 (1994) 243-247
45. Liang K., Ang K.K., Milas L., et al. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 57 (2003) 246-254
46. Sirotnak F.M., Zakowski M.F., Miller V.A., et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6 (2000) 4885-4892
47. Magne N., Fischel J.L., Dubreuil A., et al. Sequence-dependent effects of ZD1839 ("Iressa") in combination with cytotoxic treatment in human head and neck cancer. Br J Cancer 86 (2002) 819-827
48. Xu J.M., Azzariti A., Colucci G., et al. The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin in schedule-dependent in colon cancer cell lines. Cancer Chemother Pharmacol 52 (2003) 442-448
49. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 37 Suppl 4 (2001) S3-S8
50. Erjala K., Raitanen M., Kulmala J., et al. Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squanous cell carcinoma cell lines. J Cancer Res Clin Oncol 133 (2007) 169-176
51. Sergina N.V., Rausch M., Wang D., et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature 445 (2007) 437-441
52. Contessa J.N., Abell A., Mikkelsen R.B., et al. Compensatory ErbB3/c-Src signalling enhances carcinoma cell survival to ionizing radiation. Breast Cancer Res Treat 95 (2006) 17-27
53. Edelstein M.P., Lawrence A., Wolfe I.I.I., et al. Potentiation of radiation therapy by vinorelbine (Navelbine) in non-small cell lung cancer. Semin Oncol 23 (1996) 41-47
54. Hauser U., Balz V., Carey T., et al. Reliable detection of p53 aberrations in squamous cell carcinomas of the head and neck requires transcript analysis of the entire coding region. Head Neck 24 (2002) 868-873
55. Balz V., Scheckenbach K., Götte K., et al. Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human Papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 63 (2003) 1188-1191
56. Baselga J., and Averbuch S.D. ZD1839 ('Iressa') as an anticancer agent. Drugs 60 Suppl 1 (2000) 33-40 discussion 41-42
57. Depenbrock H., Shirvani A., Rastetter J., et al. Effects of vinorelbine on epidermal growth factor-receptor binding of human breast cancer cell lines in vitro. Invest New Drugs 13 (1995) 187-193